PMID- 25202105
OWN - NLM
STAT- MEDLINE
DCOM- 20141111
LR  - 20151119
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 34
IP  - 9
DP  - 2014 Sep
TI  - 8-Isoprostane in exhaled breath condensate of patients with non-small cell lung 
      cancer: the effect of chemotherapy.
PG  - 5143-5
AB  - AIM: The aim of the study was to evaluate the exhaled breath condensate (EBC) 
      levels of a valid oxidative stress marker, 8-isoprostane, before and after 
      chemotherapy, in patients with non small cell lung cancer (NSCLC) in correlation 
      with the extent of the disease and response to treatment. PATIENTS AND METHODS: 
      Forty-five patients with inoperable NSCLC were initially enrolled in the study. 
      Twenty-nine of them were finally evaluated in regards to 8-isoprostane levels in 
      EBC before and after chemotherapy. RESULTS: 8-Isoprostane levels were 
      significantly lower after chemotherapy (p=0.014). Further analysis showed that 
      the differences were mainly attributed: a) to the extent of the disease, with 
      patients diagnosed with up to locally advanced disease (stages IB-IIIB) having 
      significantly lower EBC 8-isoprostane levels post-chemotherapy (p=0.031); and b) 
      to the response to treatment, with patients evaluated with partial response to 
      treatment having significantly lower EBC 8-isoprostane levels post-chemotherapy 
      (p=0.02). CONCLUSION: In this prospective study, we showed that 8-isoprostane 
      might represent a biomarker in NSCLC, reflecting both response to chemotherapy, 
      as well as the extent of the disease.
CI  - Copyright(c) 2014 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Stathopoulos, Dimitrios
AU  - Stathopoulos D
AD  - Oncology Unit GPP, University of Athens Medical School, Sotiria General Hospital, 
      Athens, Greece dimitrios.stathopoulos@gmail.com.
FAU - Loukides, Stelios
AU  - Loukides S
AD  - Second Respiratory Medicine Department, University of Athens Medical School, 
      Attikon University Hospital, Athens, Greece.
FAU - Syrigos, Konstantinos
AU  - Syrigos K
AD  - Oncology Unit GPP, University of Athens Medical School, Sotiria General Hospital, 
      Athens, Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism/mortality/pathology
MH  - Dinoprost/*analogs & derivatives/metabolism
MH  - *Exhalation
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Oxidative Stress
MH  - Prognosis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - 8-isoprostane
OT  - Lung cancer
OT  - chemotherapy
OT  - exhaled breath condensate
EDAT- 2014/09/10 06:00
MHDA- 2014/11/12 06:00
CRDT- 2014/09/10 06:00
PHST- 2014/09/10 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2014/11/12 06:00 [medline]
AID - 34/9/5143 [pii]
PST - ppublish
SO  - Anticancer Res. 2014 Sep;34(9):5143-5.